KR102924742B1 - 이중특이적 egfr/cd16 항원-결합 단백질 - Google Patents

이중특이적 egfr/cd16 항원-결합 단백질

Info

Publication number
KR102924742B1
KR102924742B1 KR1020207029239A KR20207029239A KR102924742B1 KR 102924742 B1 KR102924742 B1 KR 102924742B1 KR 1020207029239 A KR1020207029239 A KR 1020207029239A KR 20207029239 A KR20207029239 A KR 20207029239A KR 102924742 B1 KR102924742 B1 KR 102924742B1
Authority
KR
South Korea
Prior art keywords
ser
antigen
egfr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207029239A
Other languages
English (en)
Korean (ko)
Other versions
KR20200132919A (ko
Inventor
마이클 클루게
마이클 테사르
이비카 퓨첵
크리스티나 엘완게르
우위 로이쉬
마이클 담라트
에리히 라이코비치
마틴 트레더
Original Assignee
아피메트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아피메트 게엠베하 filed Critical 아피메트 게엠베하
Publication of KR20200132919A publication Critical patent/KR20200132919A/ko
Application granted granted Critical
Publication of KR102924742B1 publication Critical patent/KR102924742B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207029239A 2018-03-14 2019-03-14 이중특이적 egfr/cd16 항원-결합 단백질 Active KR102924742B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161871.1 2018-03-14
EP18161871 2018-03-14
PCT/EP2019/056516 WO2019175368A1 (en) 2018-03-14 2019-03-14 Bispecific egfr/cd16 antigen-binding protein

Publications (2)

Publication Number Publication Date
KR20200132919A KR20200132919A (ko) 2020-11-25
KR102924742B1 true KR102924742B1 (ko) 2026-02-10

Family

ID=61683598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029239A Active KR102924742B1 (ko) 2018-03-14 2019-03-14 이중특이적 egfr/cd16 항원-결합 단백질

Country Status (13)

Country Link
US (2) US11510972B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765157A1 (cg-RX-API-DMAC7.html)
JP (1) JP7288913B2 (cg-RX-API-DMAC7.html)
KR (1) KR102924742B1 (cg-RX-API-DMAC7.html)
CN (1) CN111971090B (cg-RX-API-DMAC7.html)
AU (1) AU2019235433B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018492A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090464A1 (cg-RX-API-DMAC7.html)
IL (1) IL276903B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020009445A (cg-RX-API-DMAC7.html)
SG (1) SG11202007664WA (cg-RX-API-DMAC7.html)
WO (1) WO2019175368A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006247B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20250206823A1 (en) * 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023079493A1 (en) * 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
TW202334221A (zh) * 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
EP4562054A4 (en) * 2022-07-28 2026-08-05 Icahn School Med Mount Sinai Anti-CD16A antibodies and their methods of use
KR20240136856A (ko) * 2023-03-06 2024-09-19 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
CN121100134A (zh) * 2023-04-14 2025-12-09 山东先声生物制药有限公司 一种靶向人cd16和肿瘤抗原的多特异性抗体
WO2025167357A1 (zh) * 2024-02-06 2025-08-14 启愈生物技术(上海)有限公司 Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
CN118994409B (zh) * 2024-07-30 2025-07-22 郑州市乘黄生物医药科技有限公司 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products
EP4751734A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Bispecific antibody construct dosage regimen for treating nsclc
EP4751731A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane
EP4751777A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8289183B1 (en) 2008-04-25 2012-10-16 Texas Instruments Incorporated System and method for solar panel array analysis
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011140254A1 (en) * 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
CN105555804B (zh) * 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
CA2983706C (en) * 2015-05-04 2024-01-02 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies

Also Published As

Publication number Publication date
EP3765157A1 (en) 2021-01-20
US11510972B2 (en) 2022-11-29
MX2020009445A (es) 2020-10-08
RU2020131234A (ru) 2022-03-22
AU2019235433A1 (en) 2020-08-27
BR112020018492A2 (pt) 2020-12-29
AU2019235433B2 (en) 2025-11-20
US20200405833A1 (en) 2020-12-31
US12076384B2 (en) 2024-09-03
CA3090464A1 (en) 2019-09-19
SG11202007664WA (en) 2020-09-29
WO2019175368A1 (en) 2019-09-19
KR20200132919A (ko) 2020-11-25
ZA202006247B (en) 2021-09-29
JP2021515798A (ja) 2021-06-24
CN111971090A (zh) 2020-11-20
JP7288913B2 (ja) 2023-06-08
US20230190900A1 (en) 2023-06-22
CN111971090B (zh) 2024-02-23
IL276903B1 (en) 2025-08-01
IL276903B2 (en) 2025-12-01
IL276903A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US12076384B2 (en) Bispecific EGFR/CD16 antigen-binding protein
US20240174748A1 (en) Variable regions for nkp46 binding proteins
CN109641049B (zh) Cd3结合抗体
CN109843325B (zh) Cd3结合抗体
JP7023231B2 (ja) 最適化抗cd3二重特異性抗体及びその使用
TWI706960B (zh) 能夠結合cd19和cd3的雙特異性雙抗體及其用途
US20220049007A1 (en) Antibody molecules that bind pd-l1 and cd137
KR20250034193A (ko) Cd3-델타/엡실론 이형이량체 특이적 항체
TW202128757A (zh) 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20230227577A1 (en) Anti-dll3 antibodies and methods of use
CN106459214A (zh) 用于肿瘤治疗之方法及抗体组成物
AU2015350075A1 (en) Methods for tumor treatment using CD3xCD20 bispecific antibody
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
JP2021505637A (ja) 二重特異性cd16結合分子、及び疾患の治療におけるその使用
TW202417483A (zh) 結合nkg2d、cd16及ceacam5之蛋白質
RU2792240C2 (ru) Биспецифический антигенсвязывающий белок egfr/cd16
CA2967820C (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
HK40034502A (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
JP2022525261A (ja) ビスタ結合抗体およびその使用
HK40050345A (en) Antibody molecules that bind pd-l1 and cd137
HK40050345B (en) Antibody molecules that bind pd-l1 and cd137

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)